SCHEMBL3683176

SCHEMBL3683176

COc1ccc(-c2c(C)nn(-c3ccccn3)c2O)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC11A2 P49281 1/20 0.53
HPGD P15428 4/20 0.53
ALDH1A1 P00352 4/20 0.53
KDM4E B2RXH2 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.51
NPC1 O15118 1/20 0.51
POLB P06746 1/20 0.51
RAB9A P51151 1/20 0.51
HSD17B10 Q99714 2/20 0.45
ALOX15 P16050 1/20 0.45
NPY5R Q15761 1/20 0.44
PDCD1 Q15116 1/20 0.44
CD274 Q9NZQ7 1/20 0.44
MAPT P10636 4/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
CCNA2 P20248 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4746341 0.86 ALDH1A1 (0.48) SLC11A2HPGDALDH1A1KDM4ESMN1; SMN2
SCHEMBL3682387 0.84 SLC11A2 (0.51) SLC11A2HPGDALDH1A1KDM4ESMN1; SMN2
SCHEMBL3692788 0.84 MAPT (0.48) SLC11A2HPGDALDH1A1KDM4ESMN1; SMN2
SCHEMBL3689323 0.82 FFAR4 (0.45) HPGDALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL4745571 0.81 SLC11A2 (0.54) SLC11A2HPGDALDH1A1KDM4ESMN1; SMN2
SCHEMBL3683062 0.81 MAPT (0.52) SLC11A2HPGDALDH1A1KDM4ESMN1; SMN2
SCHEMBL3681849 0.81 SLC11A2 (0.54) SLC11A2HPGDALDH1A1KDM4ESMN1; SMN2
SCHEMBL3683412 0.80 MAPT (0.45) SLC11A2HPGDALDH1A1KDM4ESMN1; SMN2
SCHEMBL3685303 0.79 SLC11A2 (0.57) SLC11A2HPGDALDH1A1KDM4ESMN1; SMN2
SCHEMBL3693842 0.79 MEN1 (0.42) HPGDALDH1A1KDM4ESMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010005851-A1 COMBINATION THERAPY FOR TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2010-01-14 WO claimed
WO-2008121861-A2 PYRAZOLE AND PYRROLE COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2008-10-09 WO claimed
WO-2010005851-A1 COMBINATION THERAPY FOR TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2010-01-14 WO disclosed
WO-2008121861-A2 PYRAZOLE AND PYRROLE COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2008-10-09 WO disclosed
WO-2008121861-A2 PYRAZOLE AND PYRROLE COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2008-10-09 WO disclosed